Gadolinium-associated nephrogenic systemic fibrosis

Community Oncology

Volumn 5, Issue 6, 2008, Pages 325-326

  McKoy, June M ^a   Laumann, Anne ^a   Samaras, Athena ^a,b   Lacouture, Mario ^a   West, Dennis ^a   Raisch, Dennis ^c   Obadina, Eniola ^a   Fajolu, Olukemi ^a   Reilly, Lauren ^a   Bennett, Charles L ^a,b  

^a NORTHWESTERN UNIVERSITY   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c University of New Mexico   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GADOBENATE DIMEGLUMINE; GADODIAMIDE; GADOLINIUM; GADOLINIUM PENTETATE; GADOTERIDOL; GADOVERSETAMIDE;

BLADDER CANCER; CLINICAL FEATURE; DISABILITY; DISEASE COURSE; DRUG APPROVAL; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY CANCER; KIDNEY FIBROSIS; KIDNEY FUNCTION; LIVER CANCER; NEPHROGENIC SYSTEMIC FIBROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; SHORT SURVEY;

EID: 46249125103     PISSN: 15485315     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1548-5315(11)70463-6     Document Type: Short Survey

References (3)

1. Cowper SE. Nephrogenic fibrosing dermopathy: the first 6 years. Curr Opin Rheumatol 2003;15:785-790.
2. Grobner T. Gadolinium - a specific trigger for the development of nephrogenic fibrosing dermopathy and nephrogenic systemic fibrosis? Nephrol Dial Transplant 2006;21:1104-1108.
3. Gadolinium-based contrast agents for magnetic resonance imaging (marketed as Magnevist, MultiHance, Omniscan, Opti-MARK, ProHance). Available at www.fda.gov/CDER/Drug/InfoSheets/HCP/gcca_200705.htm. Accessed May 15, 2008.